These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1029 related items for PubMed ID: 7563202

  • 1. Decreased mutation rate for cellular resistance to doxorubicin and suppression of mdr1 gene activation by the cyclosporin PSC 833.
    Beketic-Oreskovic L, Durán GE, Chen KG, Dumontet C, Sikic BI.
    J Natl Cancer Inst; 1995 Nov 01; 87(21):1593-602. PubMed ID: 7563202
    [Abstract] [Full Text] [Related]

  • 2. Prevalence of multidrug resistance related to activation of the mdr1 gene in human sarcoma mutants derived by single-step doxorubicin selection.
    Chen KG, Jaffrézou JP, Fleming WH, Durán GE, Sikic BI.
    Cancer Res; 1994 Sep 15; 54(18):4980-7. PubMed ID: 7915196
    [Abstract] [Full Text] [Related]

  • 3. Mutation rates and mechanisms of resistance to etoposide determined from fluctuation analysis.
    Jaffrézou JP, Chen KG, Durán GE, Kühl JS, Sikic BI.
    J Natl Cancer Inst; 1994 Aug 03; 86(15):1152-8. PubMed ID: 8028036
    [Abstract] [Full Text] [Related]

  • 4. Multifactorial involvement of multidrug resistance-associated [correction of resistance] protein, DNA topoisomerase II and glutathione/glutathione-S-transferase in nonP-glycoprotein-mediated multidrug resistance in human bladder cancer cells.
    Kim WJ, Kakehi Y, Yoshida O.
    Int J Urol; 1997 Nov 03; 4(6):583-90. PubMed ID: 9477189
    [Abstract] [Full Text] [Related]

  • 5. Altered MRP is associated with multidrug resistance and reduced drug accumulation in human SW-1573 cells.
    Eijdems EW, Zaman GJ, de Haas M, Versantvoort CH, Flens MJ, Scheper RJ, Kamst E, Borst P, Baas F.
    Br J Cancer; 1995 Aug 03; 72(2):298-306. PubMed ID: 7640209
    [Abstract] [Full Text] [Related]

  • 6. Reversal of multidrug resistance by transduction of cytokine genes into human colon carcinoma cells.
    Stein U, Walther W, Shoemaker RH.
    J Natl Cancer Inst; 1996 Oct 02; 88(19):1383-92. PubMed ID: 8827016
    [Abstract] [Full Text] [Related]

  • 7. Doxorubicin-resistant variants of human prostate cancer cell lines DU 145, PC-3, PPC-1, and TSU-PR1: characterization of biochemical determinants of antineoplastic drug sensitivity.
    David-Beabes GL, Overman MJ, Petrofski JA, Campbell PA, de Marzo AM, Nelson WG.
    Int J Oncol; 2000 Dec 02; 17(6):1077-86. PubMed ID: 11078791
    [Abstract] [Full Text] [Related]

  • 8. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein.
    Sikic BI, Fisher GA, Lum BL, Halsey J, Beketic-Oreskovic L, Chen G.
    Cancer Chemother Pharmacol; 1997 Dec 02; 40 Suppl():S13-9. PubMed ID: 9272128
    [Abstract] [Full Text] [Related]

  • 9. Multidrug-resistant human sarcoma cells with a mutant P-glycoprotein, altered phenotype, and resistance to cyclosporins.
    Chen G, Durán GE, Steger KA, Lacayo NJ, Jaffrézou JP, Dumontet C, Sikic BI.
    J Biol Chem; 1997 Feb 28; 272(9):5974-82. PubMed ID: 9038218
    [Abstract] [Full Text] [Related]

  • 10. MDR 1 activation is the predominant resistance mechanism selected by vinblastine in MES-SA cells.
    Chen GK, Durán GE, Mangili A, Beketic-Oreskovic L, Sikic BI.
    Br J Cancer; 2000 Oct 28; 83(7):892-8. PubMed ID: 10970691
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Expression of multidrug resistance-associated protein (MRP), MDR1 and DNA topoisomerase II in human multidrug-resistant bladder cancer cell lines.
    Hasegawa S, Abe T, Naito S, Kotoh S, Kumazawa J, Hipfner DR, Deeley RG, Cole SP, Kuwano M.
    Br J Cancer; 1995 May 28; 71(5):907-13. PubMed ID: 7734314
    [Abstract] [Full Text] [Related]

  • 14. Non-P-glycoprotein-mediated atypical multidrug resistance in a human bladder cancer cell line.
    Naito S, Hasegawa S, Yokomizo A, Koga H, Kotoh S, Kuwano M, Kumazawa J.
    Jpn J Cancer Res; 1995 Nov 28; 86(11):1112-8. PubMed ID: 8567404
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. BIRICODAR (VX-710; Incel): an effective chemosensitizer in neuroblastoma.
    Yanagisawa T, Newman A, Coley H, Renshaw J, Pinkerton CR, Pritchard-Jones K.
    Br J Cancer; 1999 Jun 28; 80(8):1190-6. PubMed ID: 10376971
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 52.